Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 27, 2002

View Archived Issues

Vardenafil effective and safe as ED therapy in men with prostatectomy, CAD and hypertension

Resistance profile of Shire's anti-HIV nucleoside analogue SPD-756

Generation of HIV resistant to a potent new small-molecule CCR5 antagonist

Positive opinion handed down by CPMP for EVRA

New product for allergic conjunctivitis recommended for E.U. approval

Sho-Saiko-to to enter phase II trial in liver cancer at Memorial Sloan-Kettering

Salix NDA for Lumenax for travelers' diarrhea accepted for filing

CD4-IgG2 fusion protein highly effective in mouse model of HIV infection

Hedgehog proteins with activity in Parkinson's disease

Reliant acquires North American license to Medivir antiviral compound

Pfizer set to roll out schizophrenia treatment in Europe

PRO-140 effectively controls HIV infection via CCR5 receptor blockade in mouse model

Squalene epoxidase inhibitor FR-194738 produces less HMG-CoA reductase induction than simvastatin

Paxceed fails to meet primary objective in phase II MS study

Merck initiates development of Taisho's mglu receptor agonists

Japanese group investigates use of PTPase inhibitors in allergic diseases

CPMP recommends approval of Glivec for GISTs in Europe

Paradigm Genetics and VDDI to collaborate on antibiotic development

Zycos describes fusion polypeptides with utility in inflammatory and autoimmune diseases

Polypeptide CASB761 described in patent

Wide series claimed by Elan/Pharmacia for use in Alzheimer's disease, etc.

Scientists at BMS synthesize piperazine derivatives with anti-HIV activity

Compounds with affinity for 5-HT receptors and potential application in CNS disorders

Modulators of PTPase identified under Novo Nordisk-Ontogen joint effort

Modulators of melanin-concentrating hormone receptors discovered at Neurogen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 29, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 29, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...